INDICATIONS: HER2+ Adjuvant and Metastatic Breast Cancer, Metastatic Gastric Cancer.

PATIENT BROCHURE

TAKE THE NEXT STEP WITH KANJINTI™

LEARN MORE ABOUT:

- Your diagnosis
- Treatment with KANJINTI™

KANJINTI (trastuzumab-anns) For Injection 420mg/vial multiple dose

Patient portrayals

YOUR DIAGNOSIS

IMPORTANT SAFETY INFORMATION

What are the possible Serious Side Effects with KANJINTI™?

KANJINTI™ is not for everyone. Be sure to contact your doctor if you are experiencing any of the following potentially life threatening side effects:

HEART PROBLEMS

- These include congestive heart failure or reduced heart function—with or without symptoms. **The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product, like KANJINTI™, and a certain type of chemotherapy (anthracycline).** In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with KANJINTI™.

INFUSION REACTIONS, including:

- Fever and chills
- Feeling sick to your stomach (nausea)
- Throwing up (vomiting)
- Pain (in some cases at tumor sites)
- Headache
- Dizziness
- Shortness of breath

These signs usually happen within 24 hours after receiving KANJINTI™.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

AMGEN®

WHAT IS HER2-POSITIVE (HER2+) BREAST CANCER?

Your doctor has said that you have a type of breast cancer that is HER2+

ABOUT 1 IN 5
BREAST CANCERS ARE HER2+[1]

HER2
IS A PROTEIN
FOUND ON THE SURFACE OF HEALTHY CELLS[2]

AND HELPS CONTROL HOW CELLS[2]

Some cells may have more HER2 than is normal. This causes the cells to divide and grow faster than usual. Some may become cancer cells and spread to other areas of the body.[2]

Indications: ADJUVANT BREAST CANCER

KANJINTI™ is a prescription medicine used for the treatment of:

- **Adjuvant breast cancer**
  - KANJINTI™ is used for the treatment of early-stage breast cancer that is **H**uman **E**pidermal growth factor **R**eceptor **2**-positive (**HER2**+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.

You may hear HER2 proteins called "HER2 receptors"[2,3]

This is because they send and get information from other proteins to do their job.



When these receptors talk with one another, they make cells divide and grow.[4]

NORMAL	OVEREXPRESSED	EXCESSIVE
~ 40,000 HER2 receptors[5]	~ 1,000,000 HER2 receptors[5]	Excessive cellular division. This can lead to cells growing more and more[5]

YOU CAN ASK YOUR TREATMENT TEAM:
Now that I know I have HER2+ breast cancer, what are my next steps?

Indications: ADJUVANT BREAST CANCER (*cont'd*)

- KANJINTI™ can be used in different ways:
  - As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
  - With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
  - Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
- Patients are selected for therapy based on an FDA-approved test for trastuzumab.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™
(trastuzumab-anns)
For Injection 420mg/vial multiple dose

HOW CAN MY HER2+ BREAST CANCER BE TREATED?

It is important for women who have breast cancer to be tested for their "HER2 status"[2,6]

This tells your treatment team as soon as possible to use drugs that target the HER2 protein.

HER2 is usually found by testing a small sample of cells. The tests count the number of HER2 proteins and are done by a lab. If there are a large number of HER2 proteins, the cancer is said to be HER2+.

HER2+
TREATED WITH HER2-TARGETED DRUGS[7]

HER2-
TREATED WITH OTHER DRUGS[7]

WHY KANJINTI™?

KANJINTI™ (can-JIN-tee) can help by targeting the HER2 proteins that are causing the cells to grow and multiply.[8]

Indications: METASTATIC BREAST CANCER

- **Metastatic Breast Cancer**
  - KANJINTI™ has 2 approved uses in metastatic breast cancer:
    - KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of **H**uman **E**pidermal growth factor **R**eceptor **2**-positive (**HER2**+) metastatic breast cancer
    - KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
  - Patients are selected for therapy based on an FDA-approved test for trastuzumab.

There is treatment for your HER2+ breast cancer—it is called KANJINTI™[8]

KANJINTI™ is:

- Approved by the FDA for HER2+ breast cancer. KANJINTI™ is also known by its chemical name, trastuzumab-anns (trast-OO-zoo-mab).[8]
- A biologic, which is a drug made from a living cell. Biologic medicines are used to treat many conditions.[8,9]

KANJINTI™ works with your body's immune system to help fight cancer cells[4]

1 KANJINTI™ ATTACHES TO HER2 RECEPTORS ON CELLS.[4]

2 THIS PREVENTS CANCER CELLS FROM GROWING AND MULTIPLYING.[4,*]

*Because normal cells have HER2 receptors, KANJINTI™ can also prevent their growth and cause serious side effects.

3 THE CANCER CELL IS THEN DESTROYED BY THE BODY'S DEFENSES.[4]



NORMAL CELL

Normal cells have some HER2 receptors.[5]

HER2+ CANCER CELL

HER2+ cancer cells have many more HER2 receptors than normal cells.[5]

HER2+ CANCER CELL

KANJINTI™

FDA = Food and Drug Administration; HER2 = human epidermal growth factor receptor 2.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

WHAT IS HER2-POSITIVE (HER2+) GASTRIC CANCER?

Your doctor has said that you have a type of gastric cancer that is HER2+

ABOUT 1 IN 5
GASTRIC CANCERS ARE HER2+[10]

HER2
IS A PROTEIN
FOUND ON THE SURFACE OF
HEALTHY CELLS[2]

AND HELPS CONTROL HOW CELLS[2]

Some cells may have more HER2 than is normal. This causes the cells to divide and grow faster than usual. Some may become cancer cells and spread to other areas of the body.[2]

Indications: GASTRIC CANCER

- **Gastric Cancer**
  - KANJINTI™ is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.
  - Patients are selected for therapy based on an FDA-approved test for trastuzumab.

You may hear HER2 proteins called "HER2 receptors"[2,3]

This is because they send and get information from other proteins to do their job.



When these receptors talk with one another, they make cells divide and grow.[4]

NORMAL	OVEREXPRESSED	EXCESSIVE
~ 40,000 HER2 receptors[5]	~ 1,000,000 HER2 receptors[5]	Excessive cellular division. This can lead to cells growing more and more[5]

YOU CAN ASK YOUR TREATMENT TEAM:

Now that I know I have HER2+ gastric cancer, what are my next steps?

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

HOW CAN MY HER2+ GASTRIC CANCER BE TREATED?

It is important for people who have gastric cancer to be tested for their "HER2 status"[2,6,10]

This tells your treatment team as soon as possible to use drugs that target the HER2 protein.

HER2 is usually found by testing a small sample of cells. The tests count the number of HER2 proteins and are done by a lab. If there are a large number of HER2 proteins, the cancer is said to be HER2+.

HER2+
TREATED WITH HER2-TARGETED DRUGS[7]

HER2-
TREATED WITH OTHER DRUGS[7]

WHY KANJINTI™?

KANJINTI™ (can-JIN-tee) can help by targeting the HER2 proteins that are causing the cells to grow and multiply.[8]

IMPORTANT SAFETY INFORMATION

Tell your doctor if you:

- **Are a woman who could become pregnant, or may be pregnant.**
  - KANJINTI™ may result in the death of an unborn baby or birth defects.
  - Contraception should be used while receiving KANJINTI™ and for seven months after your last dose of KANJINTI™.
  - **Tell your doctor right away if you are exposed to KANJINTI™ during pregnancy or within 7 months of becoming pregnant.**

There is treatment for your HER2+ gastric cancer—it is called KANJINTI™[8]

KANJINTI™ is:

- Approved by the FDA for HER2+ gastric cancer. KANJINTI™ is also known by its chemical name, trastuzumab-anns (trast-OO-zoo-mab).[8]
- A biologic, which is a drug made from a living cell. Biologic medicines are used to treat many conditions.[8,9]

KANJINTI™ works with your body's immune system to help fight cancer cells[4]

1 KANJINTI™ ATTACHES TO HER2 RECEPTORS ON CELLS.[4]

2 THIS PREVENTS CANCER CELLS FROM GROWING AND MULTIPLYING.[4,*]

*Because normal cells have HER2 receptors, KANJINTI™ can also prevent their growth and cause serious side effects.

3 THE CANCER CELL IS THEN DESTROYED BY THE BODY'S DEFENSES.[4]



NORMAL CELL

Normal cells have some HER2 receptors.[5]

HER2+ CANCER CELL

HER2+ cancer cells have many more HER2 receptors than normal cells.[5]

HER2+ CANCER CELL

KANJINTI™

FDA = Food and Drug Administration; HER2 = human epidermal growth factor receptor 2.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

Proven to be as effective as Herceptin®[8,11]

KANJINTI™ is a biosimilar to the cancer drug Herceptin® and is FDA-approved for the same uses. KANJINTI™ has been tested worldwide and has been proven to have similar side effects as Herceptin®.

For more information on biosimilars and KANJINTI™, see page 18.

Can I be given KANJINTI™ if I've already started with Herceptin®?

KANJINTI™ has been proven to be as effective as Herceptin® in a study. Some patients in this study started treatment with Herceptin®, then were transitioned to KANJINTI™ for the rest of the study to make sure the side effects were similar.[11]

YOU CAN ASK YOUR TREATMENT TEAM:

- What results can I expect with KANJINTI™?

FOR MORE INFORMATION ABOUT KANJINTI™, VISIT KANJINTI.COM/PATIENTS.

IMPORTANT SAFETY INFORMATION

Tell your doctor if you *(cont'd)*:

- **Have any signs of SEVERE LUNG PROBLEMS, including:**
  - Severe shortness of breath
  - Fluid in or around the lungs
  - Weakening of the valve between the heart and the lungs
  - Not enough oxygen in the body

Amgen has a wealth of experience in bringing biologics to patients who have cancer

KANJINTI™ is made by Amgen, a world leader in cancer treatment. For 40 years, we have been developing biologics and bringing treatments to millions of people with cancer.

40
YEARS
OF EXPERIENCE

MANUFACTURER OF
17 BIOLOGIC MEDICINES*

We are deeply committed to supporting patients through their treatment journey. You can expect Amgen to deliver quality products on time and to provide support every step of the way.

AMGEN IS HERE FOR YOU WITH RESOURCES AND SUPPORT. PLEASE SEE PAGES 16–17 FOR MORE INFORMATION

*Current as of July 2019.

IMPORTANT SAFETY INFORMATION

Tell your doctor if you *(cont'd)*:

- **Have any signs of SEVERE LUNG PROBLEMS, including *(cont'd)*:**
  - Swelling of the lungs
  - Scarring of the lungs
  - Your doctor may check for signs of severe lung problems

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

Herceptin® (trastuzumab) is a registered trademark of Genentech USA, Inc.

KANJINTI™
(trastuzumab-anns)
For Injection 420mg/vial multiple dose

WHAT CAN I EXPECT WITH KANJINTI™?

A few things to keep in mind as you start KANJINTI™

Now that you know more about HER2+ cancer and KANJINTI™, you may have some questions about starting this course of therapy.

KANJINTI™ MAY BE PRESCRIBED ALONE OR WITH CHEMOTHERAPY[8]

Your doctor may choose to use KANJINTI™ with or without chemotherapy. Your doctor or nurse will discuss which combination of treatments is right for you.

KANJINTI™ IS GIVEN THROUGH AN IV INFUSION[8]

You will receive KANJINTI™ either once a week or once every 3 weeks for as long as your doctor thinks it is working for you, and as long as you are not having any serious side effects.

The points above offer only an outline of what you might expect when starting KANJINTI™. Your treatment team will make these treatment decisions with you. If your treatment plan is not clear, please talk with your treatment team.

IMPORTANT SAFETY INFORMATION

Tell your doctor if you *(cont'd)*:

- **Have LOW WHITE BLOOD CELL COUNTS**
  - Low white blood cell counts can be life threatening.
  - Low white blood cell counts were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone.
  - Your doctor may test your blood and check for signs of low white blood cell counts.

Day-of-treatment reminders

BRING A SNACK TO EAT AND SOMETHING TO DO WHILE YOU WAIT

ON ARRIVAL, YOU'LL BE EXAMINED, WEIGHED, AND ASSESSED

YOU MAY BE PROVIDED MEDICINE TO HELP PREVENT POSSIBLE SIDE EFFECTS



YOU'LL GET YOUR IV INFUSION OF KANJINTI™

AFTER YOUR INFUSION, YOUR DOCTOR WILL GIVE YOU A CHECKUP

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™
(trastuzumab-anns)
For Injection 420mg/vial multiple dose

WHAT ELSE SHOULD I KNOW ABOUT KANJINTI™?

Regular heart monitoring is important[8]

Per standard treatment with KANJINTI™, and similar drugs like Herceptin®, you will receive regular heart function checkups. These checkups will occur throughout the course of your treatment. Heart function will be tested with an ECHO or MUGA scan. An ECHO scan is an ultrasound image of the heart. A MUGA scan takes a moving picture of your heart pumping blood.[8,12]

CHECKUP **CHECKUP** **CHECKUP**

BEFORE STARTING KANJINTI™

EVERY 3–4 MONTHS DURING & UPON COMPLETION OF KANJINTI™ TREATMENT

EVERY 6 MONTHS FOR AT LEAST 2 YEARS AFTER COMPLETING KANJINTI™ THERAPY

YOU CAN ASK YOUR TREATMENT TEAM:

- Why do I need heart monitoring checkups?
- What resources can I use to choose an infusion center?

ECHO = echocardiogram; MUGA = multigated blood-pool imaging.

IMPORTANT SAFETY INFORMATION

What are the possible more common side effects of KANJINTI™?

Side Effects Seen Most Often With KANJINTI™

- **Some patients receiving trastuzumab products, like KANJINTI™, for breast cancer had the following side effects:**
  - Fever
  - Feeling sick to your stomach (nausea)
  - Throwing up (vomiting)
  - Infusion reactions
  - Diarrhea
  - Infections
  - Increased cough

WHAT TO LOOK OUT FOR

You should tell your doctor or nurse as soon as possible if you feel unwell or develop the following:[8]

- Breathlessness and cough
- Swelling in your ankles/legs or face
- Feeling your heart flutter or an irregular heartbeat
- Weight gain of more than 5 pounds in 24 hours
- Dizziness or loss of consciousness

Be sure to review the accompanying **Prescribing Information** to learn more about potential side effects and symptoms you need to watch for, to help your treatment team know when you are having a side effect.

IF YOU FEEL UNWELL DURING YOUR TREATMENT, PLEASE TELL YOUR TREATMENT TEAM

These are not all the possible side effects of KANJINTI™. For more information, ask your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch**, or call **1-800-FDA-1088**.

IMPORTANT SAFETY INFORMATION

Side Effects Seen Most Often With KANJINTI™ *(cont'd)*

- **Some patients receiving trastuzumab products, like KANJINTI™, for breast cancer had the following side effects *(cont'd)*:**
  - Headache
  - Feeling tired
  - Shortness of breath
  - Rash
  - Low white and red blood cell counts
  - Muscle pain

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

WHAT IF I NEED ADDITIONAL SUPPORT?

Whether you're a patient or a caregiver, we're here to help

If you've been prescribed KANJINTI™, you might have questions about how your medicine may be covered by your insurance. That's why we created Amgen Assist 360™—to support you in every way we can, so you can focus on what's most important to you.

AMGEN ASSIST 360™

Whatever type of insurance you have—even if you have none—your Amgen Reimbursement Counselor can help you understand how KANJINTI™ may be covered, and refer you to programs that may be able to help you afford it, such as **Amgen FIRST STEP™**.

Amgen Reimbursement Counselors can help you understand:

- **INSURANCE COVERAGE**
- **CO-PAY COSTS**
- **DEDUCTIBLE COSTS**

REFERRALS TO RESOURCES FOR DAY-TO-DAY LIVING*

We can help refer you to independent nonprofit organizations that may provide you with community resources, one-on-one counseling services, and local support groups.

To speak to an Amgen Reimbursement Counselor call: **1-888-4ASSIST** (1-888-427-7478)
• Monday to Friday 9:00 am to 8:00 pm ET
or visit **AmgenAssist360.com**

*Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits' criteria. Amgen has no control over these programs and provides referrals as a courtesy only.

AMGEN FIRST STEP™ BY AMGEN ASSIST 360™

The Amgen FIRST STEP™ Program can help eligible commercially insured patients cover their out-of-pocket prescription costs, including deductible, co-insurance, and co-payment.†

- **$0 out-of-pocket** for first dose
- **$5 out-of-pocket** for subsequent doses, **up to the program maximum** in assistance per calendar year. See **AmgenFIRSTSTEP.com** for terms and conditions
- **No income eligibility** requirement

Call **1-888-65-STEP1** (1-888-657-8371) Monday to Friday • 9:00 am to 8:00 pm ET or visit **AmgenFIRSTSTEP.com.**

The Amgen FIRST STEP™ Prepaid MasterCard is issued by Comerica Bank pursuant to license by MasterCard International Incorporated. No cash or ATM access. MasterCard is a registered trademark of MasterCard International Incorporated. This card can be used only to cover the co-payment for eligible prescriptions covered under the program at participating merchant locations where Debit MasterCard is accepted.

†Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

WHAT IS A BIOSIMILAR?

KANJINTI™ is a biologic medicine called a biosimilar[8,11]

KANJINTI™ is a biosimilar to Herceptin® and is carefully made and rigorously tested. The FDA approved KANJINTI™ for the same uses as Herceptin®. It was shown to have similar efficacy and safety to Herceptin®. Some patients in this study started treatment with Herceptin®, then were transitioned to KANJINTI™ for the rest of the study to make sure the side effects were similar.

A biosimilar is different from a "generic"[13]

Biosimilars are made to be almost identical to the original biologic drug. But it is not possible to make exact copies of biologics because they are made from living cells.

Biosimilars go through rigorous testing to demonstrate that they provide results similar to those of the original biologic drug. KANJINTI™ is made by Amgen, a world leader in biologic treatments.

IMPORTANT SAFETY INFORMATION

What are the possible more common side effects of KANJINTI™?

Side Effects Seen Most Often With KANJINTI™ *(cont'd)*

- **Some patients receiving trastuzumab products, like KANJINTI™, for metastatic stomach cancer had the following side effects:**
  - Low white blood cell counts
  - Diarrhea
  - Feeling tired
  - Low red blood cell counts
  - Swelling of the mouth lining
  - Weight loss
  - Upper respiratory tract infections
  - Fever
  - Low platelet counts
  - Swelling of the mucous membranes
  - Swelling of the nose and throat
  - Change in taste

These are not all the possible side effects of KANJINTI™. For more information, ask your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch**, or call **1-800-FDA-1088**.

Notes

This brochure is meant to help you understand your condition and your treatment. You can use this space to jot down any questions you may have for your treatment team.

Please see the full **Important Safety Information** on pages 20-21, and accompanying **Prescribing Information**, including **Boxed WARNINGS**.

KANJINTI™
(trastuzumab-anns)
For Injection 420mg/vial multiple dose

INDICATIONS

KANJINTI™ is a prescription medicine used for the treatment of:

- **Adjuvant breast cancer**
  - KANJINTI™ is used for the treatment of early-stage breast cancer that is **H**uman **E**pidermal growth factor **R**eceptor **2**-positive (**HER2**+) and that has spread into the lymph nodes, or is HER2-positive and has not spread into the lymph nodes. If it has not spread into the lymph nodes, the cancer needs to be estrogen receptor/progesterone receptor (ER/PR)-negative or have one high-risk feature. High risk is defined as ER/PR-positive with one of the following features: tumor size > 2 cm, age < 35 years, or tumor grade 2 or 3.
  - KANJINTI™ can be used in different ways:
    - As part of a treatment course including the chemotherapy drugs doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel. This treatment course is known as "AC → TH"
    - With the chemotherapy drugs docetaxel and carboplatin. This treatment course is known as "TCH"
    - Alone after treatment with multiple other therapies, including an anthracycline (doxorubicin) based therapy (a type of chemotherapy)
  - Patients are selected for therapy based on an FDA-approved test for trastuzumab.
- **Metastatic Breast Cancer**
  - KANJINTI™ has 2 approved uses in metastatic breast cancer:
    - KANJINTI™ in combination with the chemotherapy drug paclitaxel is approved for the first line treatment of **H**uman **E**pidermal growth factor **R**eceptor **2**-positive (**HER2**+) metastatic breast cancer
    - KANJINTI™ alone is approved for the treatment of HER2-positive breast cancer in patients who have received one or more chemotherapy courses for metastatic disease
  - Patients are selected for therapy based on an FDA-approved test for trastuzumab.
- **Gastric Cancer**
  - KANJINTI™ is approved, in combination with chemotherapy (cisplatin and either capecitabine or 5-fluorouracil), for the treatment of HER2-positive metastatic cancer of the stomach or gastroesophageal junction (where the esophagus meets the stomach) in patients who have not received prior treatment for their metastatic disease.
  - Patients are selected for therapy based on an FDA-approved test for trastuzumab.

IMPORTANT SAFETY INFORMATION

What are the possible Serious Side Effects with KANJINTI™?

KANJINTI™ is not for everyone. Be sure to contact your doctor if you are experiencing any of the following potentially life threatening side effects:

HEART PROBLEMS

- These include congestive heart failure or reduced heart function—with or without symptoms. **The risk for and seriousness of these heart problems were highest in people who received both a trastuzumab product, like KANJINTI™, and a certain type of chemotherapy (anthracycline)**. In a study of adjuvant (early) breast cancer, one patient died of significantly weakened heart muscle. Your doctor will check for signs of heart problems before, during, and after treatment with KANJINTI™.

INFUSION REACTIONS, including:

- Fever and chills
- Feeling sick to your stomach (nausea)
- Throwing up (vomiting)
- Pain (in some cases at tumor sites)
- Headache
- Dizziness
- Shortness of breath

These signs usually happen within 24 hours after receiving KANJINTI™.

Tell your doctor if you:

- **Are a woman who could become pregnant, or may be pregnant.**
  - KANJINTI™ may result in the death of an unborn baby or birth defects.
  - Contraception should be used while receiving KANJINTI™ and for seven months after your last dose of KANJINTI™.
  - **Tell your doctor right away if you are exposed to KANJINTI™ during pregnancy or within 7 months of becoming pregnant.**
- **Have any signs of SEVERE LUNG PROBLEMS, including:**
  - Severe shortness of breath
  - Fluid in or around the lungs
  - Weakening of the valve between the heart and the lungs
  - Not enough oxygen in the body
  - Swelling of the lungs
  - Scarring of the lungs
  - Your doctor may check for signs of severe lung problems
- **Have LOW WHITE BLOOD CELL COUNTS**
  - Low white blood cell counts can be life threatening.
  - Low white blood cell counts were seen more often in patients receiving trastuzumab plus chemotherapy than in patients receiving chemotherapy alone.
  - Your doctor may test your blood and check for signs of low white blood cell counts.

What are the possible more common side effects of KANJINTI™?

Side Effects Seen Most Often With KANJINTI™

- **Some patients receiving trastuzumab products, like KANJINTI™, for breast cancer had the following side effects:**
  - Fever
  - Feeling sick to your stomach (nausea)
  - Throwing up (vomiting)
  - Infusion reactions
  - Diarrhea
  - Infections
  - Increased cough
  - Headache
  - Feeling tired
  - Shortness of breath
  - Rash
  - Low white and red blood cell counts
  - Muscle pain
- **Some patients receiving trastuzumab products, like KANJINTI™, for metastatic stomach cancer had the following side effects:**
  - Low white blood cell counts
  - Diarrhea
  - Feeling tired
  - Low red blood cell counts
  - Swelling of the mouth lining
  - Weight loss
  - Upper respiratory tract infections
  - Fever
  - Low platelet counts
  - Swelling of the mucous membranes
  - Swelling of the nose and throat
  - Change in taste

These are not all the possible side effects of KANJINTI™. For more information, ask your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit **www.fda.gov/medwatch**, or call **1-800-FDA-1088**.

KANJINTI™
(trastuzumab-anns)
For Injection 420mg/vial multiple dose

Please see the accompanying **Prescribing Information** including **Boxed WARNINGS.**

KANJINTI™ IS HERE FOR YOU

KANJINTI™ (trastuzumab-anns) For Injection 420mg/vial multiple dose

A proven treatment[8,11]

KANJINTI™ proven similar to Herceptin® in:	KANJINTI™
EFFECTIVENESS	✓
SIDE EFFECT PROFILE	✓
DOSING ADMINISTERED EVERY 1–3 WEEKS	✓

See how we can help you understand:

- Insurance Coverage
- Co-pay Costs
- Deductible Costs

FOR SUPPORT, CALL **1-888-4ASSIST** (1-888-427-7478)
OR VISIT **AMGENASSIST360.COM**

Important Safety Information

What are the possible Serious Side Effects with KANJINTI™?
KANJINTI™ is not for everyone. Be sure to contact your doctor if you are experiencing any of the following potentially life threatening side effects *(cont'd)*:

INFUSION REACTIONS, including:

- Fever and chills
- Feeling sick to your stomach (nausea)
- Throwing up (vomiting)
- Pain (in some cases at tumor sites)
- Headache
- Dizziness
- Shortness of breath

These signs usually happen within 24 hours after receiving KANJINTI™.

Please see pages 20 and 21 of this brochure for full **Important Safety Information**, as well as the accompanying **Prescribing Information**, including **Boxed WARNINGS**.

REFERENCES: 1. Mitri Z, Constantine T, O'Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use and new advances in therapy. *Chemother Res Pract*. 2012;2012:743193. **2.** Breastcancer.org. HER2 status. www.breastcancer.org/symptoms/diagnosis/her2. Accessed June 19, 2019. **3.** Brand F-X, Ravanel N, Gauchez A-S, et al. Prospect for anti-HER2 receptor therapy in breast cancer. *Anticancer Res*. 2006;26:463-470. **4.** Breastcancer.org. How Herceptin works. www.breastcancer.org/treatment/targeted_therapies/herceptin/how_works. Accessed June 19, 2019. **5.** Onsum M, Geretti E, Paragas V, et al. Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients. *Am J Pathol*. 2013;183:1446-1460. **6.** Kumarasinghe MP, Morey A, Bilous M, et al. HER2 testing in advanced gastric and gastro-oesophageal cancer: an analysis of an Australia-wide testing program. *Pathology*. 2017;49:575-581. **7.** American Cancer Society. Breast cancer HER2 status. www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-her2-status.html. Accessed June 19, 2019. **8.** KANJINTI™ (trastuzumab-anns) Prescribing Information, Amgen. **9.** US Food and Drug Administration. What are "biologics" questions and answers. www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cber/ucm133077.htm. Accessed June 19, 2019. **10.** American Cancer Society. Targeted therapy for stomach cancer. www.cancer.org/cancer/stomach-cancer/treating/targeted-therapies.html. Accessed June 19, 2019. **11.** von Minckwitz G, Colleoni M, Kolberg HC, et al. Efficacy and safety of ABP 980 compared with reference trastuzumab in women with HER2-positive early breast cancer (LILAC study): a randomised, double-blind, phase 3 trial. *Lancet Oncol*. 2018;19:987-998. **12.** Breastcancer.org, Herceptin side effects. www.breastcancer.org. www.breastcancer.org/treatment/targeted_therapies/herceptin/side_effects. Accessed June 19, 2019. **13.** US Food and Drug Administration. Guidance for industry: scientific considerations in demonstrating biosimilarity to a reference product. www.fda.gov/downloads/drugs/guidances/ucm291128.pdf. Accessed June 19, 2019.

AMGEN®